Blog
RSS FeedPosted by Michael Wonder on 08 Oct 2020
Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
7 October 2020 - The investigators of the study set out to characterise the therapeutic value of new drugs approved ...
Posted by Michael Wonder on 28 Sep 2020
Sophisticated purchasing of pharmaceuticals: learning from other countries
28 September 2020 - In 2019 and early 2020, drug pricing in the United States was a top concern of ...
Posted by Michael Wonder on 15 Sep 2020
FDA publishes comparative performance data for COVID-19 molecular diagnostic tests
15 September 2020 - Today, the U.S. FDA published comparative performance data for some authorised COVID-19 molecular diagnostic tests. ...
Posted by Michael Wonder on 05 Sep 2020
Biocon, Mylan launch Semglee and seek biosimilar, interchangeable status
31 August 2020 - For all intents and purposes, Semglee is a biosimilar insulin, but official biosimilar status is needed to ...
Posted by Michael Wonder on 05 Sep 2020
International reference pricing: discounts down under far surpass U.S. drug price concessions
1 September 2020 - At 30,000 feet, the view of Australia’s healthcare system does not look too different from our own ...
Posted by Michael Wonder on 16 Aug 2020
Direct or indirect comparison: reliance on innovative drug data key to engaging data protection
15 August 2020 - The Federal Court recently issued its decision in Natco v Canada (Minister of Health), 2020 FC 788, ...
Posted by Michael Wonder on 19 Jul 2020
PBAC asks Roche for another comparison for Tecentriq
20 July 2020 - The submission requested a PBS (Section 100) listing for atezolizumab for use in combination with taxane chemotherapy ...
Posted by Michael Wonder on 16 Jul 2020
Assessing quantitative comparisons of health and social care between countries
15 July 2020 - Cross-national comparisons in health care and social care may offer insight into quality and cost. ...
Posted by Michael Wonder on 18 May 2020
International reference pricing gets thumbs down from ISPOR panel
18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...
Posted by Michael Wonder on 12 May 2020
A comparison of the EQ-5D-3L and EQ-5D-5L
12 May 2020 - Previous studies have found the EQ-5D-5L to have superior measurement properties but no study has compared ...
Posted by Michael Wonder on 09 Jan 2020
U.S. health care system costs four times more to run than Canada’s single payer system
7 January 2020 - In the United States, a legion of administrative health care workers and health insurance employees who ...
Posted by Michael Wonder on 30 Nov 2019
Performance of UK National Health Service compared with other high income countries: observational study
27 November 2019 - The UK’s spending on health care has been constrained for some time, with slow growth in spending ...
Posted by Michael Wonder on 25 Nov 2019
Medicine prices in Australia among the cheapest in the world, research shows
25 November 2019 - If you take medication for several health issues, you may be surprised to find out Australia has ...
Posted by Michael Wonder on 03 Nov 2019
International impact of external reference pricing: should national policy makers care?
3 November 2019 - External reference pricing is widely used to regulate drug prices. ...
Posted by Michael Wonder on 26 Oct 2019
Real-time benefit tools for drug prices
25 October 2019 - Concerns over drug prices and medication nonadherence have led to a search for new strategies to lower ...